{"DataElement":{"publicId":"5077284","version":"1","preferredName":"Recombinant Erythropoietin Administered Type","preferredDefinition":"A description of the recombinant erythropoietin that was administered.","longName":"2861436v1.0:2775108v2.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2861436","version":"1","preferredName":"Recombinant Erythropoietin Administered","preferredDefinition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous glycoprotein erythropoietin (Epo).  Epo promotes the differentiation and maturation of hematopoietic progenitors into erythrocytes; is a mitogen and a chemoattractant for endothelial cells; stimulates activated and differentiated B-cells and enhances B-cell immunoglobulin production and proliferation; and is hypoxia-inducible. (NCI04)_The act of having given something (e.g., a medication or test).","longName":"2861434v1.0:2233610v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2861434","version":"1","preferredName":"Recombinant Erythropoietin","preferredDefinition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous glycoprotein erythropoietin (Epo).  Epo promotes the differentiation and maturation of hematopoietic progenitors into erythrocytes; is a mitogen and a chemoattractant for endothelial cells; stimulates activated and differentiated B-cells and enhances B-cell immunoglobulin production and proliferation; and is hypoxia-inducible. (NCI04)","longName":"C477","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recombinant Erythropoietin","conceptCode":"C477","definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous glycoprotein erythropoietin (Epo).  Epo promotes the differentiation and maturation of hematopoietic progenitors into erythrocytes; is a mitogen and a chemoattractant for endothelial cells; stimulates activated and differentiated B-cells and enhances B-cell immunoglobulin production and proliferation; and is hypoxia-inducible. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"67B1BBA8-0657-5961-E040-BB89AD4306C0","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"67B1BBA8-0665-5961-E040-BB89AD4306C0","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-04-16","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2775108","version":"2","preferredName":"Recombinant Erythropoietin Type","preferredDefinition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous glycoprotein erythropoietin (Epo).  Epo promotes the differentiation and maturation of hematopoietic progenitors into erythrocytes; is a mitogen and a chemoattractant for endothelial cells; stimulates activated and differentiated B-cells and enhances B-cell immunoglobulin production and proliferation; and is hypoxia-inducible. (NCI04)_Type; a subdivision of a particular kind of thing.","longName":"2775108v2.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Darbepoetin alfa","valueDescription":"Darbepoetin Alfa","ValueMeaning":{"publicId":"2577851","version":"1","preferredName":"Darbepoetin Alfa","longName":"2577851","preferredDefinition":"A recombinant analog of the endogenous cytokine erythropoietin, an erythropoiesis-stimulating protein.  Due to the addition of two carbohydrate chains, darbepoetin alfa exhibits a three-fold greater half-life than does erythropoietin.  Similar to erythropoietin, darbopoietin alfa binds to and activates epoetin receptors, thereby inducing the differentiation and maturation of erythrocyte progenitors, stimulating endothelial cell proliferation, and stimulating B-cell proliferation and immunoglobulin production. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Darbepoetin Alfa","conceptCode":"C1878","definition":"A recombinant analog of the endogenous cytokine erythropoietin, an erythropoiesis-stimulating protein.  Due to the addition of two carbohydrate chains, darbepoetin alfa exhibits a three-fold greater half-life than does erythropoietin.  Similar to erythropoietin, darbopoietin alfa binds to and activates epoetin receptors, thereby inducing the differentiation and maturation of erythrocyte progenitors, stimulating endothelial cell proliferation, and stimulating B-cell proliferation and immunoglobulin production. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD28-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"22B5B587-3A9C-564F-E050-BB89AD436E50","beginDate":"2015-10-22","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-10-22","modifiedBy":"ONEDATA","dateModified":"2015-10-22","deletedIndicator":"No"},{"value":"Epoetin alfa","valueDescription":"Epoetin Alfa","ValueMeaning":{"publicId":"2576817","version":"1","preferredName":"Epoetin Alfa","longName":"2576817","preferredDefinition":"A colony-stimulating factor that is made in the laboratory. It increases the production of red blood cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epoetin Alfa","conceptCode":"C2695","definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine human erythropoietin (EPO). Produced primarily by cells of the peritubular capillary endothelium of the kidney in response to hypoxia, circulating EPO binds to EPO receptors on the surface of committed erythroid progenitors in the bone marrow resulting in their replication and maturation into functional erythrocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F91E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"ONEDATA","dateModified":"2005-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"22B5B587-3AB0-564F-E050-BB89AD436E50","beginDate":"2015-10-22","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-10-22","modifiedBy":"ONEDATA","dateModified":"2015-10-22","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2775107","version":"1","preferredName":"Recombinant Erythropoietin Type","preferredDefinition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous glycoprotein erythropoietin (Epo).  Epo promotes the differentiation and maturation of hematopoietic progenitors into erythrocytes; is a mitogen and a chemoattractant for endothelial cells; stimulates activated and differentiated B-cells and enhances B-cell immunoglobulin production and proliferation; and is hypoxia-inducible. (NCI04):Type; a subdivision of a particular kind of thing.","longName":"C477:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recombinant Erythropoietin","conceptCode":"C477","definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous glycoprotein erythropoietin (Epo).  Epo promotes the differentiation and maturation of hematopoietic progenitors into erythrocytes; is a mitogen and a chemoattractant for endothelial cells; stimulates activated and differentiated B-cells and enhances B-cell immunoglobulin production and proliferation; and is hypoxia-inducible. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54D50F72-58A5-60F3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-08-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2008-08-19","modifiedBy":"ONEDATA","dateModified":"2008-08-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"22B5B587-3A4D-564F-E050-BB89AD436E50","latestVersionIndicator":"Yes","beginDate":"2015-10-22","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-10-22","modifiedBy":"NYCHM","dateModified":"2017-01-31","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"HPST_GFCT_erythropoietin_type","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the the recombinant","type":"Preferred Question Text","description":"What was the the recombinant erythropoietin that was administered?","url":null,"context":"NHLBI"},{"name":"Specify drug given","type":"Alternate Question Text","description":"Specify drug given","url":null,"context":"NHLBI"},{"name":"Specify drug given","type":"Application Standard Question Text","description":"Specify drug given","url":null,"context":"NHLBI"},{"name":"Specify EPO drug given","type":"Alternate Question Text","description":"Specify EPO drug given","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"26659035-96DD-79FA-E050-BB89AD437FF6","latestVersionIndicator":"Yes","beginDate":"2015-12-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-08","modifiedBy":"MALUMK","dateModified":"2021-03-29","changeDescription":".AQT added for 2100r7. 03/29/2021 KMM","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}